【摘要】 [目的]比较慢性肾脏病(CKD)血液透析患者皮下注射与静脉注射促红细胞生成素(rhEPO)疗效。[方法]采用临床实验,长期血液透析患者分为皮下注射与静脉注射组,初始剂量为6000u/周(100～150u/(kg·周),分2次注射。治疗12周后监测Hb、Hct、肾功能、血电解质、ALT等水平的变化。[结果]两组患者有效率分别为93.8%(P﹤0.01)与75%(P﹤0.05)。自身比较及两组间比较(P﹤0.01)差异均有统计学意义。[结论]CKD血液透析患者皮下注射rhEPO治疗肾性贫血疗效优于静脉注射。更多还原

【Abstract】 Objective To compare effects of erythropoietin between through subcutaneous injection and intravenous injection in chronic renal disease patients receiving hemodialysis.Methods Used a clinical trial.Conducted at hemodialysis unit in our hospital,and assigned 36 patients who were receiving long-term hemodialysis and therapy with erythropoietin to be treated with either subcutaneous or intravenous injection.The initial dose was 6000u per week(100-150u per kilogram of body weight per week),which was divided into two shares to inject.Compared the changes of hemoglobin,haematocrit,renal function,blood electrolyte and alanine aminotransferase after 12-week’s maintenance phase and the discomforts associated with the two routes of administration.Results The overall response rate of the erythropoietin with subcutaneous injection was 93.8% and with intravenous injection was 75%.The differences between the two groups were significant(P﹤0.01).Conclusion The effect of erythropoietin through subcutaneous injection is more effective than through intravenous injection in the treatment of patients with anemia of chronic renal failure receiving hemodialysis.更多还原